Evidence map›Paper›PMID 39590770›Full record

ArticleMarine drugs2024

Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors and Pancreatic Islet Cell Protection by Salmon-Derived Bioactive Peptides.

Crawford Currie, Christian Bjerknes, Bomi Framroze

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Crawford CurrieHBC Immunology Inc., Menlo Park, CA 2043, USA.
Christian BjerknesHofseth BioCare, 6003 Ålesund, Norway.
Bomi FramrozeHBC Immunology Inc., Menlo Park, CA 2043, USA.ORCID 0000-0002-5251-8982

Funding

HBC Immunology HBCI 84002023
6 · The paper itself

Abstract

This study examines the in vitro effects of a soluble protein hydrolysate (SPH) derived from Atlantic salmon (Salmo salar) on incretin receptor activity and pancreatic islet cell protection to explore the mechanisms underlying SPH's observed benefits on weight loss and metabolic health in overweight individuals. SPH demonstrated a dose-dependent enhancement of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor activity, with significant increases of 2.4-fold (

Indexed as

Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsIslets of LangerhansReceptors, Gastrointestinal HormoneAnimalsCell ProliferationGlucagon-Like Peptide 1Glucagon-Like PeptidesHumansPeptidesProtein HydrolysatesSalmo salarSemaglutidegastric inhibitory polypeptide receptorGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesPeptidesProtein HydrolysatesReceptors, Gastrointestinal HormoneSemaglutideALOX12bioactive peptidesGIP receptorGLP-1 receptorhealthy ageingmetabolic healthpancreatic islet cellssalmon protein hydrolysatesoluble protein hydrolysateweight management

Identifiers

PMID39590770
PMCPMC11595994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.